Valuation dashboard for Nuvalent, Inc. (NUVL) with P/E N/A, P/B 8.30, EV/EBITDA N/A and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
Balance sheet quality for NUVL: current ratio of 15.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 8.30 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $3.22 |
| vs Current Price | -97.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NUVL | Nuvalent, Inc. | $9.1B | 8.30 | ||
| JAZZ | Jazz Pharmaceuticals plc | $15.5B | 15.84 | 3.17 | 21.4% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $9.3B | 19.78 | -0.3% | |
| AXSM | Axsome Therapeutics, Inc. | $10.9B | |||
| ABVX | Abivax S.A. | $7.5B | 15.11 | -73.9% | |
| CYTK | Cytokinetics, Incorporated | $9.1B | 119.0% | ||
| CRSP | CRISPR Therapeutics AG | $5.0B | 2.86 |
Price
| Price | $123.96 |
| Market Cap | $9.1B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABVX · ARWR · AXSM · CRSP · CYTK · JAZZ · MRUS
Explore sector: Healthcare · Biotechnology
More sections of NUVL: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks